Skip to content

Rapid Access to Contrast-Enhanced spectral mammogRaphy (RACER): a more efficient work-up of women recalled from breast cancer screening

Rapid Access to Contrast-Enhanced spectral mammogRaphy (RACER): a more efficient work-up of women recalled from breast cancer screening - RACER

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON52927
Enrollment
528
Registered
2018-01-18
Start date
2018-04-03
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer breast neoplasma

Interventions

For the intervention group, rapid access to CESM is guaranteed. Prior to the exam, a questionnaire will be used to screen for risk factors for using iodine-based contrast agents (this is common prac
(2) a negative CESM exam with no suspect lesion on both low-energy and recombined image
(3) CESM exam, including targeted ultrasound, and core biopsy or fine needle cytology aspiration for pathological diagnosis
(4) like group 3. Since many false-positive recalls are caused either by cysts or by superimpos

Sponsors

Medisch Universitair Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Included are women able to provide informed consent and recalled from breast cancer screening for a suspicious breast lesion during the 18-month study inclusion period.

Exclusion criteria

Exclusion criteria: Exclusion criteria are contra-indications for the use of iodine-based contrast agents (allergies), severe renal insufficiency or risk for contrast-induced nephropathy.

Design outcomes

Primary

MeasureTime frame
Primary study parameters are the diagnostic performance of CESM as compared to conventional mammography, defined as sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV), area under the ROC curve (AUC).

Secondary

MeasureTime frame
Secondary study outcomes are days to final diagnosis for both study arms, patient experienced anxiety (as measured by State-Trait Anxiety Inventory (STAI) and EQ5D questionnaires) for both approaches, and a cost-effectiveness and budget impact analysis.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)